- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01878708
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an open-label, investigator-initiated, single-arm pilot study. Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) will receive Oncaspar® every 3 weeks up to a maximum of 8 courses or until disease progression or unacceptable toxicity. They will also receive dexamethasone 40mg daily for 4 days with every cycle. They will be restaged after 2 courses (6 weeks) and after 8 courses (24 weeks).
Both Oncaspar and dexamethasone have been used together to treat ALL and ENKTL, which is another subtype of T cell lymphoma. The combination may provide a collaborative attack against the cancer cell; moreover, the dexamethasone could also prevent some of the side effects of Oncaspar; especially allergic reactions. This study will test these two drugs together to determine if they are an effective treatment for T-Cell Lymphoma. Each drug is commercially available to the drug market.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must meet the following criteria on screening examination to be eligible to participate in the study:
- Patients must have histologically confirmed peripheral T-cell lymphoma, with the diagnostic specimen reviewed at one of the DFHCC hematopathology laboratories. Eligible histologies include:
- PTCL-NOS
- Systemic T cell/null anaplastic large cell lymphoma (ALCL), regardless of Alk status
- Angioimmunoblastic T-cell lymphoma (AITL)
- Hepatosplenic (alpha-beta or gamma-delta) lymphoma (HSL)
- Enteropathy-associated T-cell lymphoma (EATL)
- Adult T-cell leukemia/lymphoma (ATLL), lymphomatous subtype
- Subcutaneous panniculitis-like T-cell lymphoma
- T-cell Prolymphocytic Leukemia (T-PLL)
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan
- Patients must have relapsed or progressed after at least 1 prior course of anti-lymphoma therapy.
- Age 18-65 years.
- ECOG performance status <2 (see Appendix A).
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study.
- Patients with cutaneous disease only are not eligible.
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier to grade 1 or below (unless approved by the Study Chair).
- Patients may not be receiving any other study agents at the time of first treatment.
- History of treatment with an asparaginase agent.
- Patients with a history of alcohol abuse, or patients unwilling or unable to remain completely abstinent of alcohol during the study period.
- Hepatitis B or C seropositivity (except for hepatitis B with negative surface antigen and hepatitis B viral load).
- Total bilirubin > institutional upper limit of normal (ULN), unless due to hemolysis or Gilbert's disease).
- AST/ALT ≥ 3 x ULN.
- History of pancreatitis, or amylase > ULN or lipase > ULN.
- History of thromboembolic disease.
- Grade 2 or above neuropathy.
- Diabetes mellitus, unless it is type II diabetes adequately controlled with anti-diabetic agents (A1c < 7).
- History of CNS hemorrhage or thrombosis. Patients with a history of CNS lymphomatous involvement are eligible only if their CNS disease is in remission at the time of study entry.
- Uncontrolled intercurrent illness including, but not limited to uncontrolled active infection, symptomatic congestive heart failure (New York Hospital Association (NYHA) class II-IV, resulting in at least slight limitation of activity), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Inability to provide informed consent
- Pregnancy or lactation.
- Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
- HIV-positive individuals on combination antiretroviral therapy are ineligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PEG-L-asparaginase/Dexamethasone
Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
|
Other Names:
-dexamethasone 40mg daily for 4 days with every cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response rate (complete + partial response) in evaluable patients.
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response for patients with PR or CR
Time Frame: 24 weeks
|
24 weeks
|
|
Grade 2 and above attributable toxicity of treatment.
Time Frame: 24 weeks
|
24 weeks
|
|
Progression-free survival.
Time Frame: 1 year
|
This will be assessed in both evaluable patients and in responders.
|
1 year
|
Complete remission (CR) rate.
Time Frame: 24 weeks
|
This will be assessed both in the intent-to-treat and in the evaluable populations.
|
24 weeks
|
Partial remission (PR) rate.
Time Frame: 24 weeks
|
This will be assessed both in the intent-to-treat and in the evaluable populations.
|
24 weeks
|
The stable disease (SD) rates in this population and in the intent-to-treat population
Time Frame: 24 weeks
|
24 weeks
|
|
Progressive disease (PD) rate.
Time Frame: 24 weeks
|
This will be assessed both in the intent-to-treat and in the evaluable populations.
|
24 weeks
|
Stable disease (SD) rate.
Time Frame: 24 weeks
|
This will be assessed both in the intent-to-treat and in the evaluable populations.
|
24 weeks
|
Overall survival
Time Frame: 1 year
|
This will be assessed in both evaluable patients and in responders.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Phillippe Armand, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Asparaginase
- Pegaspargase
Other Study ID Numbers
- 13-165
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on T-Cell Lymphoma
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
National Cancer Institute (NCI)WithdrawnHepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Extranodal NK-/T-cell Lymphoma, Nasal Type | Monomorphic Epiteliotrophic Intestinal T-cell LymphomaUnited States
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Yonsei University; Korea Cancer...CompletedCutaneous T Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | Angioimmunoblastic T Cell Lymphoma | Peripheral T Cell Lymphoma UnspecifiedKorea, Republic of
-
National Cancer Institute (NCI)CompletedPeripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)United States
-
Deepa JagadeeshRecruitingAngioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Enteropathy Associated T-cell Lymphoma | Hepato-splenic T-cell Lymphoma | NK T-cell LymphomaUnited States
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
-
University of NebraskaNational Cancer Institute (NCI); AmgenCompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Recurrent Adult T-cell Leukemia/LymphomaUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...SuspendedAngioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | Anaplastic Lymphoma | Acute T Cell Leukemia | T-lymphoblastic LymphomaChina
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
Clinical Trials on PEG-L-asparaginase
-
Children's Oncology GroupRecruitingLymphoblastic Lymphoma | B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia, BCR-ABL1-LikeUnited States, Canada
-
Rigshospitalet, DenmarkNordic Society for Pediatric Hematology and OncologyCompletedAcute Lymphoblastic LeukemiaFinland, Denmark, Norway, Sweden, Iceland
-
Fudan UniversityCompleted
-
Nordic Society for Pediatric Hematology and OncologyDanish Child Cancer Foundation; Medac, Hamburg, GermanyUnknownAcute Lymphoblastic LeukemiaDenmark
-
M.D. Anderson Cancer CenterCompleted
-
Phoenix Children's HospitalJazz Pharmaceuticals; Fisher BioservicesNo longer availableAcute Lymphoid Leukemia | Leukemia, Acute Lymphoblastic
-
ERYtech PharmaCentre Leon BerardCompletedAcute Lymphoblastic LeukemiaFrance
-
Hunan Cancer HospitalRecruitingChemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic DisorderChina
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; Servier Pharmaceuticals...RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8United States
-
medac GmbHSyneos HealthRecruitingAcute B-Cell Lymphoblastic LeukaemiaBrazil